Indacaterol - The First Once-daily Long-acting Beta2 Agonist for COPD (Hardcover, 2014 ed.)

Chronic obstructive pulmonary disease (COPD) is a multi-component condition that results in increasingly limited airflow, usually associated with an abnormal inflammatory response of the lung. It constitutes a major public health burden worldwide, while only very few effective therapies are available. This book provides a comprehensive overview of the development of Onbrez Breezhaler, a newly approved once-daily inhaled ?2 agonist for the treatment of COPD. It reviews the current pharmacotherapy for COPD and discusses topics such as the chemical design and the pre-clinical pharmacology of the molecule, the early clinical development, the INHANCE study (which provides a successful example of the use of an adaptive design in the confirmatory setting) and the Phase III clinical efficacy study, as well as the history and performance of the Breezhaler device. Finally, a list of emerging targets is included that could well offer future treatment options for COPD.

General

Imprint:	Springer Basel
Country of origin:	Switzerland
Series:	Milestones in Drug Therapy
Release date:	November 2013
First published:	2014
Editors:	Alexandre Trifilieff
Dimensions:	235 x 155 x 15mm (L x W x T)
Format:	Hardcover
Pages:	146
Edition:	2014 ed.
ISBN-13:	978-3-03-480708-1
Categories:	Books > Medicine > Clinical & internal medicine > Respiratory medicine Books > Medicine > Other branches of medicine > Pharmacology > General Promotions
LSN:	3-03-480708-2
Barcode:	9783034807081

Is the information for this product incomplete, wrong or inappropriate? Let us know about it.

Does this product have an incorrect or missing image? Send us a new image.

Is this product missing categories? Add more categories.

Review This Product

No reviews yet - be the first to create one!